المؤلفون: Shabani, Zahra, Schuerger, Joana, Zhu, Xiaonan, Tang, Chaoliang, Ma, Li, Yadav, Alka, Liang, Rich, Press, Kelly, Weinsheimer, Shantel, Schmidt, Annika, Wang, Calvin, Sekhar, Abinav, Nelson, Jeffrey, Kim, Helen, Su, Hua

المصدر: Cells. 13(1)

مصطلحات موضوعية: brain arteriovenous malformation, collagen I, collagen III, depletion of microglia, gluycoprotein nonmetastatic B, microhemorrhage, Humans, Animals, Mice, Endothelial Cells, Brain, Arteriovenous Malformations, Hemorrhage, Collagen Type I

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/3ct221f8Test

المؤلفون: Yu Fan, Xuanjun Guo, Davide Campobasso, Zhisong He

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: nonmetastatic castration-resistant prostate cancer (nmCRPC), second-generation androgen receptor inhibitors (SGARIs), choice behavior, quality of life, physicians, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1382678/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/7d073e6136d1440dbedc4494411abf17Test

المؤلفون: Shengming Ran, Jingtian Yang, Jintao Hu, Liekui Fang, Wang He

المصدر: Current Oncology, Vol 30, Iss 12, Pp 10166-10178 (2023)

مصطلحات موضوعية: nonmetastatic muscle-invasive bladder cancer, trimodality therapy, predictive model, SEER database, nomogram, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/30/12/740Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/faf91f34985b483aba0631a8e82501c2Test

المؤلفون: Takuya Tsujino, Satoshi Tokushige, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Takaya Ohno, Keita Nakamori, Ryoichi Maenosono, Kazuki Nishimura, Shogo Yamazaki, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Fumihiko Urabe, Shunsuke Tsuzuki, Kosuke Iwatani, Shutaro Yamamoto, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma

المصدر: Cancer Medicine, Vol 12, Iss 19, Pp 19414-19422 (2023)

مصطلحات موضوعية: abiraterone acetate, androgen receptor signaling inhibitor, castration‐resistant prostate cancer, enzalutamide, nonmetastatic castration‐resistant prostate cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/a557172dfc5b4cd6bd24118ee1dcb769Test

المؤلفون: Carles, Joan, Medina Lopez, Rafael A., Puente, Javier, Gómez Ferrer, Álvaro, Casas Nebra, Javier, Sáez Medina, María Isabel, Ribal, Maria J., Rodríguez Antolín, Alfredo, Álvarez-Ossorio Fernández, José Luis, Suárez Novo, José Francisco, Moretones Agut, Cristina, Srinivasan, Shankar, Ortiz, Jorge, Fizazi, Karim

المساهمون: Cirugía

المصدر: Future Oncology. Vol. 19, nº 12, April 2023, pp. 819 - 828

مصطلحات موضوعية: androgen receptor inhibitor, castration-resistant prostate cancer, darolutamide, metastasis-free survival, nonmetastatic, prostate-specific antigen, PSA progression, Spain, Spanish

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10498/31131Test

الإتاحة: https://doi.org/10.2217/fon-2022-1131Test
http://hdl.handle.net/10498/31131Test

المؤلفون: B. Ya. Alekseev, V. M. Perepukhov, K. M. Nyushko, Б. Я. Алексеев, В. М. Перепухов, К. М. Нюшко

المصدر: Cancer Urology; Том 19, № 4 (2023); 167-175 ; Онкоурология; Том 19, № 4 (2023); 167-175 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: тройная комбинация, nonmetastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, high progression risk, combination therapy, double combination, triple combination, неметастатический кастрационно-рефрактерный рак предстательной железы, метастатический гормоночувствительный рак предстательной железы, высокий риск прогрессирования, комбинированная терапия, двойная комбинация

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1790/1503Test; Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал 2023;22(5):5–13. DOI:10.21294/1814-4861-2023-22-5-5-13; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI:10.1056/NEJMoa040720; Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI:10.1200/JCO.2017.75.3657; Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI:10.1056/NEJMoa1704174; Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI:10.1056/NEJMoa1903835; Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormonesensitive prostate cancer. J Clin Oncol 2019;37(32):2974–86. DOI:10.1200/JCO.19.00799; Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI:10.1056/NEJMoa1903307; Fizazi K., Foulon S., Carles J. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. Lancet 2022;399(10336):1695–707. DOI:10.1016/S0140-6736(22)00367-1; Markham A., Duggan S. Darolutamide: first approval. Drugs 2019;79(16):1813–8. DOI:10.1007/s40265-019-01212-y; Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. DOI:10.1056/NEJMoa2119115; Bowling G.C., Dimitrakoff J.D. Darolutamide in metastatic prostate cancer. N Engl J Med 2022;386(24):2344. DOI:10.1056/NEJMc2205310; Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46. DOI:10.1056/NEJMoa1503747; Clarke N.W., Ali A., Ingleby F.C. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [published correction appears in Ann Oncol 2020;31(3):442]. Ann Oncol 2019;30(12):1992–2003. DOI:10.1093/annonc/mdz396; Fizazi K., Tran N., Fein L. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686–700. DOI:10.1016/S1470-2045(19)30082-8; James N.D., de Bono J.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI:10.1056/NEJMoa1702900; Hussain M., Tombal B., Saad F. et al. Darolutamide plus androgendeprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41(20):3595–607. DOI:10.1200/JCO.23.00041; Preisser F., Chun F.K., Banek S. et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int 2021;9(3):113–8. DOI:10.1016/j.prnil.2020.12.003; Wenzel M., Würnschimmel C., Nocera L. et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus 2022;8(2):399–408. DOI:10.1016/j.euf.2021.04.003; Mandel P., Hoeh B., Wenzel M. et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus 2023;9(1):96–105. DOI:10.1016/j.euf.2022.08.007; Sathianathen N.J., Pan H.Y.C., Lawrentschuk N. et al. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: an updated systematic review and network meta-analysis. Urol Oncol 2023;41(5):233–9. DOI:10.1016/j.urolonc.2022.10.016; Yanagisawa T., Rajwa P., Thibault C. et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol 2022;82(6):584–98. DOI:10.1016/j.eururo.2022.08.002; Maiorano B.A., de Giorgi U., Roviello G. et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open 2022;7(5):100575. DOI:10.1016/j.esmoop.2022.100575; Roy S., Sayyid R., Saad F. et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network metaanalysis. Eur Urol Oncol 2022;5(5):494–502. DOI:10.1016/j.euo.2022.06.003; Mori K., Mostafaei H., Sari Motlagh R. et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network metaanalysis. BJU Int 2022;129(4):423–33. DOI:10.1111/bju.15507; Chi K.N. LATITUDE study – final analysis of phase III study in patients with newly diagnosed high-risk metastatic castrationnaïve prostate cancer. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, February 14–16, 2019, San Francisco, CA.; Chi K.N., Chowdhury S., Bjartell A. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294–303. DOI:10.1200/JCO.20.03488; Armstrong A. Final overall survival analysis from ARCHES: a phase 3, randomized, double-blind, placebo-controlled study of enzalutamide + ADT in men with mHSPC. Presented at the 2021 European Society for Medical Oncology Annual Congress, September 16–21, 2021.; Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and longterm survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70(2):256–62. DOI:10.1016/j.eururo.2015.11.005; James N.D. Abiraterone acetate plus prednisolone for hormonenaïve prostate cancer: long-term results from metastatic (M1) patients in the STAMPEDE randomized trial. Presented at the 2020 European Society for Medical Oncology Virtual Congress, September 19–21, 2020.; Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI:10.1016/S1470-2045(12)70560-0; Dou M., Liang H., Liu Y. et al. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. J Cancer Res Clin Oncol 2023;149(10):7017–27. DOI:10.1007/s00432-023-04658-6; Borgmann H., Lallous N., Ozistanbullu D. et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol 2018;73(1):4–8. DOI:10.1016/j.eururo.2017.08.012; Shore N., Zurth C., Fricke R. et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14(5):527–39. DOI:10.1007/s11523-019-00674-0; Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer [published correction appears in N Engl J Med 2022;387(9):860]. N Engl J Med 2019;380(13):1235–46. DOI:10.1056/NEJMoa1815671; https://oncourology.abvpress.ru/oncur/article/view/1790Test

الإتاحة: https://doi.org/10.17650/1726-9776-2023-19-4-167-175Test
https://doi.org/10.21294/1814-4861-2023-22-5-5-13Test
https://doi.org/10.1056/NEJMoa040720Test
https://doi.org/10.1200/JCO.2017.75.3657Test
https://doi.org/10.1056/NEJMoa1704174Test
https://doi.org/10.1056/NEJMoa1903835Test
https://doi.org/10.1200/JCO.19.00799Test
https://doi.org/10.1056/NEJMoa1903307Test
https://doi.org/10.1016/S0140-6736Test(22)00367-1
https://doi.org/10.1007/s40265-019-01212-yTest

المؤلفون: Zahra Shabani, Joana Schuerger, Xiaonan Zhu, Chaoliang Tang, Li Ma, Alka Yadav, Rich Liang, Kelly Press, Shantel Weinsheimer, Annika Schmidt, Calvin Wang, Abinav Sekhar, Jeffrey Nelson, Helen Kim, Hua Su

المصدر: Cells, Vol 13, Iss 1, p 92 (2024)

مصطلحات موضوعية: brain arteriovenous malformation, collagen I, collagen III, microhemorrhage, depletion of microglia, gluycoprotein nonmetastatic B, Cytology, QH573-671

العلاقة: https://www.mdpi.com/2073-4409/13/1/92Test; https://doaj.org/toc/2073-4409Test; https://doaj.org/article/f8a5d4898637431194463104c0117eeaTest

الإتاحة: https://doi.org/10.3390/cells13010092Test
https://doaj.org/article/f8a5d4898637431194463104c0117eeaTest

المؤلفون: Can Li, Xiaohui Luan, Xiao Bi, Shengxin Chen, Yue Pan, Jingfeng Zhang, Yun Han, Xiaodan Xu, Guanyun Wang, Baixuan Xu

المصدر: BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)

مصطلحات موضوعية: PET, Nonmetastatic gallbladder cancer, Cholecystitis, Multiparameter, Metabolic parameters, differential diagnosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/cc031bbccd1a4af89ddc7d230ef2700fTest

المؤلفون: Larco Coloma, Jesús Nicolás, Valenzuela Cifuentes, Marco, Araujo Parra, Milton, Pungacho Espin, Nathalie Estephania, Bucheli Proaño, Patricio, Salgado, Byron, Larco Noboa, Nicolás

المصدر: International Journal of Medical and Surgical Sciences; Vol. 11 No. 2 (2024): June, 2024; 1-7 ; International Journal of Medical and Surgical Sciences; Vol. 11 Núm. 2 (2024): Junio, 2024; 1-7 ; 0719-532X ; 0719-3904 ; 10.32457/ijmss.v11i2

مصطلحات موضوعية: Giant solitary fibroma, Mesenchymal tumor, lung neoplasia, lung tumor, giant fibroid, nonmetastatic tumor, Fibroma solitario gigante, Tumor mesenquimal, neoplasia pulmonar, tumor pulmonar, fibroma gigante, tumor no metastasico

وصف الملف: application/pdf; application/epub+zip

العلاقة: https://revistas.uautonoma.cl/index.php/ijmss/article/view/2493/1785Test; https://revistas.uautonoma.cl/index.php/ijmss/article/view/2493/1786Test; https://revistas.uautonoma.cl/index.php/ijmss/article/view/2493Test

الإتاحة: https://doi.org/10.32457/ijmss.v11i2.249310.32457/ijmss.v11i2Test
https://revistas.uautonoma.cl/index.php/ijmss/article/view/2493Test

المؤلفون: Koji Mita, Kouji Izumi, Akihiro Goriki, Ryo Tasaka, Tomoya Hatayama, Takashi Shima, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono, Atsushi Mizokami

المصدر: Cancers, Vol 16, Iss 3, p 508 (2024)

مصطلحات موضوعية: abiraterone, enzalutamide, castration-resistant, nonmetastatic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/16/3/508Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/0c8d0708dc23486bb9e1a381da9eb6cfTest